Goldman Sachs
AUTL

Goldman Sachs’s Autolus Therapeutics AUTL Stock Holding History

Goldman Sachs’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Sell
113,556
-2,857
-2% -$4.48K ﹤0.01% 6221
2026
Q1 		$161K Buy
116,413
+88,664
+320% +$135K ﹤0.01% 6139
2025
Q4 		$55.2K Sell
27,749
-466,004
-94% -$716K ﹤0.01% 6275
2025
Q3 		$805K Buy
493,753
+469,647
+1,948% +$918K ﹤0.01% 5187
2025
Q2 		$55K Sell
24,106
-26,305
-52% -$43.5K ﹤0.01% 5900
2025
Q1 		$78.1K Sell
50,411
-75,819
-60% -$154K ﹤0.01% 5830
2024
Q4 		$297K Buy
126,230
+66,218
+110% +$224K ﹤0.01% 5500
2024
Q3 		$218K Sell
60,012
-18,352
-23% -$73.2K ﹤0.01% 5426
2024
Q2 		$273K Sell
78,364
-137,977
-64% -$595K ﹤0.01% 5145
2024
Q1 		$1.38M Buy
216,341
+84,610
+64% +$528K ﹤0.01% 4123
2023
Q4 		$848K Buy
131,731
+64,910
+97% +$248K ﹤0.01% 4468
2023
Q3 		$156K Sell
66,821
-26,374
-28% -$75.2K ﹤0.01% 5102
2023
Q2 		$222K Buy
93,195
+71,378
+327% +$169K ﹤0.01% 5144
2023
Q1 		$40.1K Buy
+21,817
New +$42.7K ﹤0.01% 5581
2022
Q4 		– Sell
-18,851
Closed -$40K – 5975
2022
Q3 		$40K Sell
18,851
-2,188
-10% -$6.48K ﹤0.01% 5825
2022
Q2 		$60K Sell
21,039
-354,475
-94% -$1.08M ﹤0.01% 5990
2022
Q1 		$1.57M Buy
375,514
+222,093
+145% +$934K ﹤0.01% 4443
2021
Q4 		$796K Buy
153,421
+97,030
+172% +$582K ﹤0.01% 5041
2021
Q3 		$369K Sell
56,391
-594,105
-91% -$3.75M ﹤0.01% 5373
2021
Q2 		$4.32M Buy
650,496
+639,002
+5,559% +$3.97M ﹤0.01% 3466
2021
Q1 		$66K Sell
11,494
-2,891
-20% -$21.4K ﹤0.01% 5906
2020
Q4 		$129K Sell
14,385
-13,189
-48% -$141K ﹤0.01% 5240
2020
Q3 		$321K Sell
27,574
-7,058
-20% -$102K ﹤0.01% 4702
2020
Q2 		$555K Sell
34,632
-3,756
-10% -$41.6K ﹤0.01% 4320
2020
Q1 		$230K Buy
38,388
+27,672
+258% +$256K ﹤0.01% 4642
2019
Q4 		$141K Sell
10,716
-13,295
-55% -$174K ﹤0.01% 4985
2019
Q3 		$298K Buy
+24,011
New +$317K ﹤0.01% 4688
2019
Q2 		– Sell
-8,720
Closed -$274K – 5115
2019
Q1 		$274K Buy
8,720
+2,026
+30% +$57.6K ﹤0.01% 4673
2018
Q4 		$220K Buy
+6,694
New +$220K ﹤0.01% 4778

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs's AUTL Position: Q2 2026 in Review

Goldman Sachs reduced its Autolus Therapeutics (AUTL) stake by 2.5% in Q2 2026, selling an estimated $4.48K and leaving 113,556 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #6221.

Goldman Sachs first reported a position in AUTL in Q4 2018 and has held it in 29 quarters since. The position peaked at $4.32M in Q2 2021. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Goldman Sachs held 113,556 shares of Autolus Therapeutics worth $182K as of Q2 2026.
  • Goldman Sachs sold 2,857 Autolus Therapeutics shares in Q2 2026, an estimated $4.48K.
  • Autolus Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6221 holding.
  • Goldman Sachs first reported a position in Autolus Therapeutics in Q4 2018 and has held it in 29 quarters since.
  • Goldman Sachs's Autolus Therapeutics position peaked at $4.32M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.